ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. American Society of Health-System Pharmacists.
Stroke is a catastrophic, but largely preventable, consequence of AF. ASHP supports recommendations established by the American College of Chest Physicians (Table 1) for the use of antithrombotic therapy in appropriate patients to reduce the morbidity and mortality associated with stroke. The selection of warfarin versus aspirin should be based on the presence of clinical risk factors for stroke and the patient's ability to safely undergo anticoagulation therapy. Adequate patient education and monitoring are keys to the successful use of antithrombotic therapy, and ASHP believes that pharmacists can play an important role in providing these services.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000191:economics / Q000592:standards*; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin